Anebulo PharmaceuticalsANEB
13F holders, Q4 2024 (December 31)15holders +2
2new positions
0sold out
$1.65avg. 13F price*
At the end of Q4 2024, 15 institutions reported holding Anebulo Pharmaceuticals Inc. (ANEB) in their 13F filings, up 2 from Q3 2024. 2 opened new positions and 0 sold out. The largest holders were 22NW, LP ($26.0M), Nantahala Capital Management, LLC ($5.1M) and Mangrove Partners Im, LLC ($3.6M).
- Company
- Anebulo Pharmaceuticals Inc.
- CUSIP
- 034569103
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $3.7M |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 15,236,158 shares bought and 9,545 shares sold, net +15,226,613 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| 22NW, LP | 16.39% | Add +188.2% | 15,467,300 | $26.0M |
| Nantahala Capital Management, LLC | 0.36% | Add +494.1% | 3,036,325 | $5.1M |
| Mangrove Partners Im, LLC | 0.44% | New | 2,525,252 | $3.6M |
| LVW Advisors, LLC | 0.13% | Reduce -1.3% | 632,516 | $1.1M |
| Morgan Stanley | 0.00% | Add +5.2% | 419,994 | $706K |
| Ikarian Capital, LLC | 0.08% | Reduce -0.1% | 157,720 | $265K |
| Vanguard Group Inc. | 0.00% | No change | 154,036 | $259K |
| Geode Capital Management, LLC | 0.00% | Add +4.0% | 91,341 | $153K |
| King Luther Capital Management Corp. | 0.00% | New | 59,662 | $100K |
| Boothbay Fund Management, LLC | 0.00% | Reduce -0.8% | 18,836 | $32K |
| BlackRock, Inc. | 0.00% | Add +0.6% | 3,929 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +23.5% | 3,326 | $6K |
| Bank of America Corp. | 0.00% | No change | 76 | $128 |
| UBS Group AG | 0.00% | Reduce -96.7% | 25 | $42 |
| JPMorgan Chase & Co. | 0.00% | No change | 9 | $15 |
"% of holder's portfolio" is ANEB's weight in each manager's 13F, not the share of Anebulo Pharmaceuticals Inc. the manager owns.